Correlation between cell survival and micronuclei formation in V79 cells treated with vindesine before exposure to different doses of γ-radiation

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 448, Issue 1, 2000, Pages 57-68

  Jagetia, Ganesh Chandra ^a   Adiga, Satish Kumar ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Cell proliferation index; Micronuclei; Radiation; Survival; V79 cells; Vindesine

Indexed keywords

VINDESINE;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL GROWTH; CELL SURVIVAL; GAMMA IRRADIATION; GENOTOXICITY; MICRONUCLEUS; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; CELL LINE; CELL SURVIVAL; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FIBROBLASTS; GAMMA RAYS; LUNG; MICRONUCLEUS TESTS; VINDESINE;

ANIMALIA;

EID: 0034646279     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00240-7     Document Type: Article

References (53)

1. Math G., Mist J.L., De vassal F., Gousei J., Hyatt M., Machover D., Beldame D., Pico J.L., Schwarzen-berg L., Ribbed P., Musket M., Jasmine C.L., De Luca L. Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease absence of cross resistance with vincristine. Cancer Treat. Rep. 62:1978;805-809.
2. Garewal H.S., Brooks R.J., Jones S.E, Miller T.P. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. J. Clin. Oncol. 1:1983;772-775.
3. Houwen B., Ockahuizen Th., Marrink J., Nie Weg H.O. Vindesine therapy melphalan resistant multiple myeloma. Eur. J. Cancer. 17:1981;227-232.
4. Krivit W., Chilcote R., Pyesmany A., Anderson J., Hammond D. An initial report of a phase III trial comparing vindesine and vincristine for acute leukemia of childhood. Cancer Chemother. Pharmacol. 2:1979;267-270.
5. Mandelli F., Amadori S., Giona F., Antonietta M., Spiriti A., Pastore S., Meloni G., Paolucci G. Vindesine in the treatment of refractory haemolytic malignancies, a phase II study. Leukaemia Res. 6:1982;649-652.
6. Jordan M.A., Whims R.H., Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 45:1985;2741-2747.
7. Djaldetti M. Ultra structural alteration of normal blood cells and leukemic lymphoblasts incubated with vindesine. Biomed. Pharmacother. 45:1991;343-347.
8. Sweeney M.J., Boder G.B., Cullinan G.C., Culp H.W., Daniels W.D., Dyke R.W., Gerzon K., Mcmahon R.E., Nelson R.L., Poore G.A., Todd G.C. Antitumor activity of desacetyl vinblastine amide sulphate (vindesine) in rodents and mitotic accumulation studies in culture. Cancer Res. 38:1978;886-891.
9. Jagetia G.C., Adiga S.K. Influence of vindesine exposure on the micronucleus formation and cell survival in V79 cells. Mutat. Res. 421:1998;55-63.
10. Jagetia G.C., Jyothi P. Enhancement of micronuclei frequency by vindesine in mice bone marrow. Mutat. Res. 388:1997;1-5.
11. Balla I., Michel C., Fritz-Niggli H. Synergistic interaction between vindesine and X-rays in the prenatal development of mice. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 52:1987;371-383.
12. Jagetia G.C., Jyothi P., Krishnamurthy H. Flow cytometric evaluation of the effects of various doses of vindesine sulphate on mouse spermatogenesis. Reprod. Toxicol. 11:1997;867-874.
13. Sandberg A.A. The Chromosome in Human Cancer and Leukemia. 1980;Elsevier, New York.
14. Hecht F., Hecht B.K. Vig B.K., Sandberg A.A. Aneuploidy in Humans: Dimensions, Demography, and Dangers of Abnormal Numbers of Chromosomes. 1987;9-49 Alan R. Liss, New York.
15. Sieber S.M., Adamson R.H. Toxicity of antineoplastic agents in man, chromosomal aberrations antifertility effects, congenital malformations, and carcinogenic potential. Adv. Cancer Res. 22:1975;57-155.
16. Matney T.S., Nguyen T.V., Connor T.H., Dana W.J., Theiss J.C. Genotoxic classification of anticancer drugs. Teratogen. Carcinogen. Mutagen. 5:1985;319-328.
17. Rosner F., Grunwald H. Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. Am. J. Med. 57:1974;927-939.
18. Coltman C.A. jr., Dixon D.O. Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. Cancer Treat. Rep. 66:1982;1023-1033.
19. Schmahl D., Habs M., Lorenz M., Wagner I. Occurrence of second tumors in man after anticancer drug treatment. Cancer Treat. Rev. 9:1982;167-194.
20. Krepinsky A., Bryant D.W., Davison L., Young B., Heddle J., McCalla D.R., Douglass G., Michalko K. Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ. Mol. Mutagen. 15:1990;83-92.
21. UNSCEAR report, Ionizing radiation sources and biological effects, United Nations, New York, USA, 1982, pp. 7-33, 727-765.
22. Puck T.T., Marcus P.I. A rapid method for viable cell titration and clone production with HeLa cells in tissue culture. The use of X-irradiated cells to supply conditioning factors. Proc. Natl. Acad. Sci. U.S.A. 41:1955;432-437.
23. Fenech M., Morley A.A. Measurement of micronuclei in lymphocytes. Mutat Res. 147:1985;29-36.
24. Countryman P.I, Heddle J.A. The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat. Res. 41:1976;321-332.
25. Jagetia G.C., Jacob P.S. The influence of vinblastine treatment on the formation of radiation-induced micronuclei in mouse bone marrow. Hereditas. 120:1994;51-59.
26. Edelstein M.P., Wolfe L.A., Duch D.S. Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin. Oncol. 23(Suppl. 5):1996;41-47.
27. van Rijn J., van den Berg J., Meijer O.W. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int. J. Radiat. Oncol. Biol. Phys. 33:1995;635-639.
28. Elomaa L., Joensuu H., Kulmala J., Klemi P., Grenman R. Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol Stockholm. 115:1995;340-344.
29. Jaakkola M., Rantanen V., Grenman S., Kulmala J., Grenman R. In vitro concurrent paclitaxel and radiation of four vulvar squmous cell carcinoma cell lines. Cancer. 77:1996;1940-1946.
30. Rodriguez M., Sevin B.U., Peras J., Nguyvn H.N., Pham C., Steren A.J., Koechli O.R., Averette H.E. Paclitaxel: a radiation sensitizer of human cervical cancer cells. Gynecol. Oncol. 57:1995;165-169.
31. Mote P.A., Davey M.W., Davey R.A., Oliver L. Paclitaxel sensitizes multidrug resistant cells to radiation. Anticancer Drugs. 7:1996;182-188.
32. Jagetia G.C., Adiga S.K. Correlation between micronuclei-induction and cell survival in V79 cells exposed to paclitaxel (taxol) in conjunction with radiation. Mutat. Res. 337:1997;105-113.
33. Howard S.M.H., Theolodiges A., Sheppard J.R. Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells. Cancer Res. 40:1980;2695-2700.
34. Jagetia G.C., Nayak V. Micronuclei-induction and its correlation to cell survival in HeLa cells treated with different doses of adriamycin. Cancer Lett. 110:1996;123-128.
35. Jagetia G.C., Adiga S.K. Influence of various concentrations of taxol on cell survival, micronuclei induction, and LDH activity in cultured V79 cells. Cancer Lett. 96:1995;195-200.
36. Kligerman A.D., King S.C. Frequency of micronucleated binucleated lymphocytes is not significantly affected by the harvest time following G0 exposure to X-irradiation. Int. J. Radiat. Biol. 68:1995;19-23.
37. Jagetia G.C., Nayak V., Vidyasagar M.S. Evaluation of the antineoplastic activity of Guduchi (Tinospora cordifolia) in cultured HeLa cells. Cancer Lett. 127:1998;71-82.
38. Bernstam V.A., Gray R.H., Bernstein I.A. Effect of microtubule disrupting drugs on protein and RNA synthesis in Physarum polycephalum amoebae. Arch. Microbiol. 128:1980;34-40.
39. Dustin P. Microtubules. 2nd edn. 1984;Springer, Berlin.
40. Creasy W.A. Modifications in biochemical pathways produced by the Vinca alkaloids. Cancer Chemother. Res. 52:1968;501-507.
41. Kohn K.W. DNA target in cancer chemotherapy: Measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Methods Cancer Res. 16:1979;291-345.
42. Obe G., Natarajan A.T., Palitti F. Role of double-strand breaks in the formation of radiation-induced chromosomal aberrations. Mutat. Res. 4:1982;1-9.
43. Natarajan A.T., Darroudi F., Mullenders L.H., Meijers F. The nature and repair of DNA lesions that lead to chromosomal aberrations induced by ionizing radiations. Mutat. Res. 160:1986;231-236.
44. Midander J., Revesz L. The frequency of micronuclei as a measure of cell survival in irradiated cell populations. Int. J. Radiat. Biol. 38:1980;237-242.
45. Streffer C., van Beuningen D., Molls M. Possibilities of micronucleus test as an assay in radiotherapy. Krächer K.H., Kogelnik H.D., Reinartz G. Progress in Radiooncology II. 1982;243-251 Raven Press, New York.
46. Geard C.R., Chen C.Y. Micronuclei and clonogenicity following low and high dose rate gamma-irradiation of normal human fibroblasts. Radiat. Res. 124:1990;S56-S61.
47. Mariya Y., Streffer C., Fuhrman C., Wojcik A. Correlation of radiation-induced micronucleus frequency with clonogenic survival in cells of one diploid and two tetraploid murine tumor cell lines of the same origin. Radiat. Res. 147:1997;29-34.
48. Bush C., McMillan T.J. Micronucleus formation in human tumor cells: lack of correlation with radiosensitvity. Br. J. Cancer. 67:1993;102-106.
49. Au W.W. Monitoring human populations for effects of radiation and chemical exposures using cytogenetic techniques. Occupational Medicine Philadelphia. 6:1991;597-611.
50. Weisburger E.K. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer. 40:1977;1935-1949. (Suppl.).
51. Pedersen-Bjergaard J., Rowley J.D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 83:1994;2780-2786.
52. Roth S., Nora H., Jarventaus P., Ahonen J., Sorsa M. Analysis of chromosomal aberrations, sister chromatid exchanges and micronuclei in peripheral lymphocytes of pharmacists before and after working with cytostatic drugs. Mutat. Res. 325:1994;157-162.
53. Oestricher U., Glatzel S.G. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat. Res. 242:1990;271-277.